These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 16680462

  • 1. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

  • 2. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
    Veltkamp SA, Rosing H, Huitema AD, Fetell MR, Nol A, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):635-42. PubMed ID: 17205304
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, Rowinsky EK.
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JH.
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):347-54. PubMed ID: 11345652
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX.
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [Abstract] [Full Text] [Related]

  • 8. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 9. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
    Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema AD, Nuijen B, Nol A, Beijnen JH, Schellens JH.
    Br J Cancer; 2006 Sep 18; 95(6):729-34. PubMed ID: 16926835
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.
    Clin Cancer Res; 2002 May 18; 8(5):1038-44. PubMed ID: 12006516
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of oral paclitaxel.
    Malingré MM, Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Huinink WW, Swart M, Lieverst J, Schellens JH.
    J Clin Oncol; 2000 Jun 18; 18(12):2468-75. PubMed ID: 10856107
    [Abstract] [Full Text] [Related]

  • 12. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.
    Cancer Chemother Pharmacol; 2007 Jun 18; 60(1):81-9. PubMed ID: 17031646
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 18; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
    Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD.
    Clin Cancer Res; 2007 Jun 01; 13(11):3293-301. PubMed ID: 17545535
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.